Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Immunother Cancer. 2021 Apr;9(4). doi: 10.1136/jitc-2020-002086.
Cancer virotherapy is a paradigm-shifting treatment modality based on virus-mediated oncolysis and subsequent antitumor immune responses. Clinical trials of currently available virotherapies showed that robust antitumor immunity characterizes the remarkable and long-term responses observed in a subset of patients. These data suggest that future therapies should incorporate strategies to maximize the immunotherapeutic potential of oncolytic viruses. In this review, we highlight the recent evidence that the antiviral immunity of the patients may limit the immunotherapeutic potential of oncolytic viruses and summarize the most relevant approaches to strategically redirect the immune response away from the viruses and toward tumors to heighten the clinical impact of viro-immunotherapy platforms.
癌症病毒疗法是一种基于病毒介导的肿瘤溶解和随后的抗肿瘤免疫反应的治疗模式的重大转变。目前可用的病毒疗法的临床试验表明，强大的抗肿瘤免疫是观察到一部分患者显著和长期反应的特征。这些数据表明，未来的治疗方法应该包括最大限度地发挥溶瘤病毒免疫治疗潜力的策略。在这篇综述中，我们强调了最近的证据，即患者的抗病毒免疫可能会限制溶瘤病毒的免疫治疗潜力，并总结了最相关的方法，以战略性地将免疫反应从病毒转向肿瘤，以提高病毒免疫治疗平台的临床影响。
Zotero 插件